Publications

Drug delivery and translational research

Clinical pharmacokinetics of an amorphous solid dispersion tablet of elacridar.

01-02-2017

Journal of neurology

Strategies to target drugs to gliomas and CNS metastases of solid tumors.

01-03-2016

Nature

Tumour-specific proline vulnerability uncovered by differential ribosome codon reading.

25-02-2016

Behavioural brain research

Neurobiological changes by cytotoxic agents in mice.

15-02-2016

Molecular pharmaceutics

Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo.

07-12-2015

International journal of cancer

ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2-Inhibitors.

15-10-2015

Investigational new drugs

P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib.

01-10-2015

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Plasma membrane targeting by short chain sphingolipids inserted in liposomes improves anti-tumor activity of mitoxantrone in an orthotopic breast carcinoma xenograft model.

01-08-2015

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.

01-03-2015

Cell reports

Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch in Cell Fate Resulting in Tumor Progression.

20-01-2015

Psychopharmacology

Cognitive impact of cytotoxic agents in mice.

01-01-2015

Investigational new drugs

"Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183".

01-12-2014

International journal of cancer

In vivo disposition of doxorubicin is affected by mouse Oatp1a/1b and human OATP1A/1B transporters.

01-10-2014

Clinical cancer research : an official journal of the American Association for Cancer Research

ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy.

15-05-2014

Molecular cancer therapeutics

OATP1A/1B transporters affect irinotecan and SN-38 pharmacokinetics and carboxylesterase expression in knockout and humanized transgenic mice.

01-02-2014

PloS one

Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101).

15-01-2014

Brain imaging and behavior

Chemotherapy-related cognitive dysfunction: current animal studies and future directions.

01-12-2013

Cancer research

Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma.

15-11-2013

Investigational new drugs

Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA.

01-10-2013

International journal of cancer

Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2.

01-09-2013

Nature communications

Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin.

30-05-2013

CNS oncology

Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux.

01-05-2013

European journal of cancer (Oxford, England : 1990)

Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo.

01-05-2013

Clinical cancer research : an official journal of the American Association for Cancer Research

Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.

15-04-2013

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Sensitive method for plasma and tumor Ko143 quantification using reversed-phase high-performance liquid chromatography and fluorescence detection.

15-01-2013

PloS one

EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.

03-10-2012

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Determination of NVP-BEZ235, a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography with fluorescence detection.

15-07-2012

Investigational new drugs

Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP.

01-04-2012

Journal of clinical pharmacology

From mouse to man: predictions of human pharmacokinetics of orally administered docetaxel from preclinical studies.

01-03-2012

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

High-performance liquid chromatography analysis of a novel small-molecule, anti-cancer drug, Palomid 529, in human and mouse plasma and in mouse tissue homogenates.

15-12-2011

Investigational new drugs

Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice.

01-10-2011

Drug metabolism and disposition: the biological fate of chemicals

Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate.

01-08-2011

Clinical cancer research : an official journal of the American Association for Cancer Research

High impact of Oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel.

15-01-2011

Clinical cancer research : an official journal of the American Association for Cancer Research

Rapid and robust transgenic high-grade glioma mouse models for therapy intervention studies.

01-07-2010

Proceedings of the National Academy of Sciences of the United States of America

Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation.

20-04-2010

Investigational new drugs

Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice.

01-04-2010

Cancer research

Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.

15-02-2010

Clinical cancer research : an official journal of the American Association for Cancer Research

P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide.

01-01-2010

Cancer research

Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity.

01-12-2009

Cancer treatment reviews

High-grade glioma mouse models and their applicability for preclinical testing.

01-12-2009

Molecular cancer therapeutics

Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo.

01-12-2009

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography.

01-11-2009

Clinical cancer research : an official journal of the American Association for Cancer Research

Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo.

01-05-2009

Investigational new drugs

The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib.

01-02-2009

Current clinical pharmacology

Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743).

01-01-2009

Clinical cancer research : an official journal of the American Association for Cancer Research

Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate.

15-12-2008

Drug metabolism and disposition: the biological fate of chemicals

Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice.

01-08-2008

Molecular cancer therapeutics

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.

01-08-2008

Molecular cancer therapeutics

In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.

01-12-2007

The Journal of clinical investigation

Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.

01-11-2007

Clinical pharmacokinetics of an amorphous solid dispersion tablet of elacridar.

Strategies to target drugs to gliomas and CNS metastases of solid tumors.

Tumour-specific proline vulnerability uncovered by differential ribosome codon reading.

Neurobiological changes by cytotoxic agents in mice.

Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo.

ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2-Inhibitors.

P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib.

Plasma membrane targeting by short chain sphingolipids inserted in liposomes improves anti-tumor activity of mitoxantrone in an orthotopic breast carcinoma xenograft model.

Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.

Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch in Cell Fate Resulting in Tumor Progression.

Cognitive impact of cytotoxic agents in mice.

"Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183".

In vivo disposition of doxorubicin is affected by mouse Oatp1a/1b and human OATP1A/1B transporters.

ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy.

OATP1A/1B transporters affect irinotecan and SN-38 pharmacokinetics and carboxylesterase expression in knockout and humanized transgenic mice.

Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101).

Chemotherapy-related cognitive dysfunction: current animal studies and future directions.

Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma.

Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA.

Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2.

Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin.

Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux.

Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo.

Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.

Sensitive method for plasma and tumor Ko143 quantification using reversed-phase high-performance liquid chromatography and fluorescence detection.

EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.

Determination of NVP-BEZ235, a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography with fluorescence detection.

Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP.

From mouse to man: predictions of human pharmacokinetics of orally administered docetaxel from preclinical studies.

High-performance liquid chromatography analysis of a novel small-molecule, anti-cancer drug, Palomid 529, in human and mouse plasma and in mouse tissue homogenates.

Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice.

Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate.

High impact of Oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel.

Rapid and robust transgenic high-grade glioma mouse models for therapy intervention studies.

Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation.

Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice.

Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.

P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide.

Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity.

High-grade glioma mouse models and their applicability for preclinical testing.

Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo.

Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography.

Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo.

The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib.

Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743).

Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate.

Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice.

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.

In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.

Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.

This site uses cookies